Envestnet Asset Management
CANF

Envestnet Asset Management’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Envestnet Asset Management’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-71
Closed -$25K – 3281
2020
Q3 		$25K Buy
71
+10
+16% +$4.17K ﹤0.01% 3081
2020
Q2 		$24K Buy
+61
New +$22.5K ﹤0.01% 3045

Other funds holding CANF

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Envestnet Asset Management's CANF Position: Q4 2020 in Review

Envestnet Asset Management sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q4 2020, closing a stake of 71 shares — an estimated $25K sold.

Envestnet Asset Management first reported a position in CANF in Q2 2020 and held it in 2 quarters. The position peaked at $25K in Q3 2020. 6 funds tracked by Wall St. Rank hold CANF as of Q4 2020.

  • Envestnet Asset Management reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q4 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 71 Can-Fite BioPharma American Depositary Shares shares in Q4 2020, an estimated $25K.
  • Envestnet Asset Management first reported a position in Can-Fite BioPharma American Depositary Shares in Q2 2020 and held it in 2 quarters.
  • Envestnet Asset Management's Can-Fite BioPharma American Depositary Shares position peaked at $25K in Q3 2020.
  • 6 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2020.

Based on Envestnet Asset Management's 13F filing for Q4 2020, filed 2 Feb 2021.